Targets › ZN
3 programs from 3 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 3; Metabolic and endocrine, Infectious disease, Hematology; next expected readout Jul 2027.
Open in Phaseline: the race on ZN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Maryland, Baltimore | Zinc Gluconate 30 MG Zinc supplementation to improve glucose homeostasis | ZN | Phase 4 | Prediabetic State | Jul 2028 |
| Harvard School of Public Health (HSPH) | Zinc Supplements (dispersible zinc citrate tablets) Elemental zinc supplementation | ZN | Phase 3 | Neonatal Infection | Oct 2027 |
| University of California, San Francisco | Zinc gluconate 25 mg/day Zinc supplementation | ZN | Phase 2 | Sickle Cell Disease | Jul 2027 |
Sickle Cell Disease (2) Prediabetic State (1) Neonatal Infection (1)
small molecule (2)
University of Maryland, Baltimore (1) Harvard School of Public Health (HSPH) (1) University of California, San Francisco (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.